| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
19,319 |
16,749 |
$1.02M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
4,262 |
4,023 |
$243K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
4,676 |
4,200 |
$180K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
3,650 |
3,434 |
$124K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,667 |
1,552 |
$78K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
5,661 |
2,645 |
$51K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
3,627 |
3,475 |
$28K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,503 |
2,090 |
$23K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
307 |
293 |
$12K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
228 |
220 |
$11K |
| 81002 |
|
1,104 |
962 |
$2K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,820 |
1,535 |
$1K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
31 |
26 |
$990.91 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
255 |
203 |
$293.12 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
32 |
27 |
$34.24 |
| 99000 |
|
181 |
173 |
$0.00 |